European Pharmaceutical Review
DECEMBER 20, 2023
1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted. analysis (Source: L.E.K) About the authors Sean Dyson is a Partner in L.E.K.’s
European Pharmaceutical Review
SEPTEMBER 12, 2023
As part of The Future of Pharma/Biopharma Analysis 2023 , which took place on 28-29 June 2023, European Pharmaceutical Review ( EPR ) gathered an expert panel to discuss developing a modern contamination control strategy. Early adopters started putting these strategies together around 20 years ago.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 6, 2022
As a result, 2022 saw a breakthrough when the first ever computationally designed antibody created by Israel-based Biolojic design entered clinical trial , further fuelling the interest of biopharma companies. Biopharma companies are not the only ones watching this space keenly. AI for accelerated antibody discovery. AI Novo biotech.
pharmaphorum
AUGUST 4, 2022
It was supposed to enrol 200 subjects and generate results in 2014. Pfizer acquired PF-07265803 went it bought Array BioPharma in 2019 for $11.4 The decision to stop development of PF-07265803 comes after of interim futility analysis concluded the study was unlikely to meet its primary endpoint. One study found that around 7.5%
pharmaphorum
JANUARY 24, 2023
A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.
Clarivate
OCTOBER 31, 2023
What do the years 2001, 2007, 2014, and 2022 have in common? Investment strategy Industry commentators in the biopharma industry believe the upcoming years are expected to be a period of increased dealmaking activity. In short, the biotech bubble had burst.
pharmaphorum
JANUARY 27, 2023
Also reported this month were the drastic steps that need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to the Medicines Manufacturing Industry Partnership (MMIP), set up by the UK government and biopharma industry in 2014 to drive growth in the category.
Expert insights. Personalized for you.
83 
Let's personalize your content